In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients

Lipids in Health and Disease

Volumn 13, Issue 1, 2014, Pages

  Papakonstantinou, Vasiliki D ^a   Chini, Maria ^b   Mangafas, Nikos ^b   Stamatakis, George M ^a   Tsogas, Nickolaos ^b   Tsoupras, Alexandros B ^a   Psarra, Katherina ^c   Fragopoulou, Elizabeth ^d   Antonopoulou, Smaragdi ^d   Gargalianos, Panagiotis ^e   Demopoulos, Constantinos A ^a   Lazanas, Marios C ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b RED CROSS HOSPITAL   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

^d HAROKOPIO UNIVERSITY   (Greece)

^e G GENNIMATAS GENERAL HOSPITAL   (Greece)

Author keywords

Abacavir; Cardiovascular disease; Cytokines; Efavirenz; Human immunodeficiency virus; Inflammation; Platelet activating factor; Tenofovir DF

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; EMTRICITABINE; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LAMIVUDINE; LOW DENSITY LIPOPROTEIN; TENOFOVIR; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; LEUKOCYTE; MALE; THROMBOCYTE; ANALOGS AND DERIVATIVES; ANIMAL; HIV INFECTIONS; METABOLISM; MIDDLE AGED;

HUMAN IMMUNODEFICIENCY VIRUS;

ADENINE; ADULT; ANIMALS; ANTI-HIV AGENTS; BENZOXAZINES; HIV INFECTIONS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; INTERLEUKIN-8; LAMIVUDINE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PLATELET ACTIVATING FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84902551687     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-13-90     Document Type: Article

References (46)

1. Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy. Taiwo B, Barcena L, Tressler R, Curr HIV/AIDS Rep 2013 10 21 32 10.1007/s11904-012-0147- 3
2. HIV and inflammation: mechanisms and consequences. Hunt PW, Curr HIV/AIDS Rep 2012 9 139 147 10.1007/s11904-012-0118-8
3. Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary. Plaeger SF, Collins BS, Musib R, Deeks SG, Read S, Embry A, AIDS Res Hum Retroviruses 2012 28 469 477 21854232
4. Adjudicated Morbidity and Mortality Outcomes by Age among Individuals with HIV Infection on Suppressive Antiretroviral Therapy. Miller CJ, Baker JV, Bormann AM, Erlandson KM, Huppler Hullsiek K, Justice AC, Neuhaus J, Paredes R, Petoumenos K, Wentworth D, Winston A, Wolfson J, Neaton JD, Insight S, Groups ES, PloS one 2014 9 95061 10.1371/journal.pone.0095061 24728071
5. Role of Cytokines and Chemokines in HIV Infection. Venketaraman V, Morris D, Donohou C, Sipin A, Kung S, Oh H, Franklin M, Murad JP, Khasawneh FT, Saviola B, Guilford T, Donahue C, HIV and AIDS-Updates on Biology, Immunology, Epidemiology and Treatment Strategies Croatia: InTech, Dumais N, 2011 281 300
6. Abacavir alters the transcription of inflammatory cytokines in virologically suppressed, HIV-infected women. MacLeod IJ, Rowley CF, Lockman S, Ogwu A, Moyo S, van Widenfelt E, Mmalane M, Makhema J, Essex M, Shapiro RL, J Int AIDS Soc 2012 15 17393 22789611
7. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. Lundgren J, Neuhaus J, Babiker A, Cooper D, Duprez D, El-Sadr W, Emery S, Gordin FM, Kowalska J, Phillips A, Prineas R, Reiss P, Sabin CA, Tracy R, Weber R, Grund B, Neaton J, AIDS 2008 22 17 F24 18753925
8. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. Palella FJ Jr, Gange SJ, Benning L, Jacobson L, Kaplan RC, Landay AL, Tracy RP, Elion R, AIDS 2010 24 1657 1665 10.1097/QAD.0b013e3283389dfa 20588104
9. Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. Padilla S, Masia M, Garcia N, Jarrin I, Tormo C, Gutierrez F, BMC Infect Dis 2011 11 40 10.1186/1471-2334-11-40 21294867
10. Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells. Kim C, Gupta SK, Green L, Taylor BM, Deuter-Reinhard M, Desta Z, Clauss M, Antivir Ther 2011 16 1335 1339 22155915
11. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl- 3-phosphorylcholine as the active component (a new class of lipid chemical mediators). Demopoulos CA, Pinckard RN, Hanahan DJ, J Biol Chem 1979 254 9355 9358 489536
12. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM, Crit Care Med 2002 30 294 S301 10.1097/00003246-200205001- 00020 12004251
13. Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM, Crit Rev Clin Lab Sci 2003 40 643 672 10.1080/714037693 14708958
14. Platelet activating factor-a molecular link between atherosclerosis theories. Demopoulos CA, Karantonis HC, Antonopoulou S, Eur J Lipid Sci Technol 2003 105 705 716 10.1002/ejlt.200300845
15. Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes [published errata appear in Biochim Biophys Acta 1995 Aug 3;1257(3):297 and 1995 Oct 26;1259(1):121]. Snyder F, Acta Biochim Biophys 1995 1254 231 249 10.1016/0005-2760(94)00192-2
16. CDP-choline:alkylacetylglycerol cholinephosphotransferase catalyzes the final step in the de novo synthesis of platelet-activating factor. Snyder F, Bba-Lipid Lipid Met 1997 1348 111 116 10.1016/S0005-2760(97)00109-4
17. A single enzyme catalyzes both platelet-activating factor production and membrane biogenesis of inflammatory cells. Cloning and characterization of acetyl-CoA:LYSO-PAF acetyltransferase. Shindou H, Hishikawa D, Nakanishi H, Harayama T, Ishii S, Taguchi R, Shimizu T, J Biol Chem 2007 282 6532 6539 17182612
18. Human plasma platelet-activating factor acetylhydrolase. Purification and properties. Stafforini DM, Prescott SM, McIntyre TM, J Biol Chem 1987 262 4223 4230 3558407
19. Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: implications for the neuropathogenesis of HIV disease. Genis P, Jett M, Bernton EW, Boyle T, Gelbard HA, Dzenko K, Keane RW, Resnick L, Mizrachi Y, Volsky DJ, Epstein LG, Gendelman HE, J Exp Med 1992 176 1703 1718 10.1084/jem.176.6.1703 1460427
20. Tat-induced platelet-activating factor synthesis contributes to the angiogenic effect of HIV-1 Tat. Del Sorbo L, Arese M, Giraudo E, Tizzani M, Biancone L, Bussolino F, Camussi G, Eur J Immunol 2001 31 376 383 10.1002/1521-4141(200102)31:2<376::AID-IMMU376>3.0.CO;2-5 11180101
21. Motility induced by human immunodeficiency virus-1 Tat on Kaposi's sarcoma cells requires platelet-activating factor synthesis. Biancone L, Cantaluppi V, Boccellino M, Bussolati B, Del Sorbo L, Conaldi PG, Albini A, Toniolo A, Camussi G, Am J Pathol 1999 155 1731 1739 10.1016/S0002-9440(10) 65488-0 10550329
22. Platelet-activating factor receptor activation. An initiator step in HIV-1 neuropathogenesis. Perry SW, Hamilton JA, Tjoelker LW, Dbaibo G, Dzenko KA, Epstein LG, Hannun Y, Whittaker JS, Dewhurst S, Gelbard HA, J Biol Chem 1998 273 17660 17664 10.1074/jbc.273.28.17660 9651362
23. HIV-1 Tat protein stimulates in vivo vascular permeability and lymphomononuclear cell recruitment. Arese M, Ferrandi C, Primo L, Camussi G, Bussolino F, J Immunol 2001 166 1380 1388 10.4049/jimmunol.166.2.1380 11145723
24. HIV-1 Tat reduces nephrin in human podocytes: a potential mechanism for enhanced glomerular permeability in HIV-associated nephropathy. Doublier S, Zennaro C, Spatola T, Lupia E, Bottelli A, Deregibus MC, Carraro M, Conaldi PG, Camussi G, AIDS 2007 21 423 432 10.1097/QAD.0b013e328012c522 17301560
25. Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection? Tsoupras AB, Chini M, Tsogas N, Fragopoulou E, Nomikos T, Lioni A, Mangafas N, Demopoulos CA, Antonopoulou S, Lazanas MC, Aids Res Human Retroviruses 2008 24 1079 1086 10.1089/aid.2007.0263
26. PMS-601, a new platelet-activating factor receptor antagonist that inhibits human immunodeficiency virus replication and potentiates zidovudine activity in macrophages. Martin M, Serradji N, Dereuddre-Bosquet N, Le Pavec G, Fichet G, Lamouri A, Heymans F, Godfroid JJ, Clayette P, Dormont D, Antimicrob Agents Chemother 2000 44 3150 3154 10.1128/AAC.44.11.3150-3154.2000 11036039
27. Structure-activity relationships in platelet-activating factor. Part 14: synthesis and biological evaluation of piperazine derivatives with dual anti-PAF and anti-HIV-1 activity. Sallem W, Serradji N, Dereuddre-Bosquet N, Dive G, Clayette P, Heymans F, Bioorg Med Chem 2006 14 7999 8013 10.1016/j.bmc.2006.07. 043 16908170
28. Structure-activity relationships in platelet-activating factor. Part 13: synthesis and biological evaluation of piperazine derivatives with dual anti-PAF and anti-HIV-1 or pure antiretroviral activity. Serradji N, Bensaid O, Martin M, Sallem W, Dereuddre-Bosquet N, Benmehdi H, Redeuilh C, Lamouri A, Dive G, Clayette P, Heymans F, Bioorg Med Chem 2006 14 8109 8125 10.1016/j.bmc.2006.07. 031 16893650
29. Platelet-activating factor and its basic metabolic enzymes in blood of naive HIV-infected patients. Tsoupras AB, Chini M, Mangafas N, Tsogas N, Stamatakis G, Tsantila N, Fragopoulou E, Antonopoulou S, Gargalianos P, Demopoulos CA, Lazanas MC, Angiology 2012 63 343 352 10.1177/0003319711420608 21948973
30. Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Khovidhunkit W, Memon RA, Shigenaga JK, Pang M, Schambelan M, Mulligan K, Feingold KR, Grunfeld C, Metabolism 1999 48 1524 1531 10.1016/S0026-0495(99) 90240-8 10599983
31. Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders. Eggert D, Dash PK, Serradji N, Dong CZ, Clayette P, Heymans F, Dou H, Gorantla S, Gelbard HA, Poluektova L, Gendelman HE, J Neuroimmunol 2009 213 47 59 10.1016/j.jneuroim.2009.06.002 19541372
32. Reduction in glial immunity and neuropathology by a PAF antagonist and an MMP and TNFalpha inhibitor in SCID mice with HIV-1 encephalitis. Persidsky Y, Limoges J, Rasmussen J, Zheng J, Gearing A, Gendelman HE, J Neuroimmunol 2001 114 57 68 10.1016/S0165-5728(00)00454-9 11240016
33. Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium. Schifitto G, Sacktor N, Marder K, McDermott MP, McArthur JC, Kieburtz K, Small S, Epstein LG, Neurology 1999 53 391 396 10.1212/WNL.53.2.391 10430432
34. Effects of HAART on platelet-activating factor metabolism in naive HIV-infected patients I: study of the tenofovir-DF/emtricitabine/efavirenz HAART regimen. Chini M, Tsoupras AB, Mangafas N, Tsogas N, Papakonstantinou VD, Fragopoulou E, Antonopoulou S, Gargalianos P, Demopoulos CA, Lazanas MC, AIDS Res Hum Retroviruses 2012 28 766 775 10.1089/aid.2011.0202 22050695
35. Effects of highly active antiretroviral therapy on platelet activating factor metabolism in naive HIV-infected patients: ii) study of the abacavir/lamivudine/efavirenz HAART regimen. Chini M, Tsoupras AB, Mangafas N, Tsogas N, Papakonstantinou VD, Fragopoulou E, Antonopoulou S, Gargalianos P, Demopoulos CA, Lazanas MC, Int J Immunopathol Pharmacol 2012 25 247 258 22507337
36. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. Clumeck N, Pozniak A, Raffi F, Committee EE, HIV medicine 2008 9 65 71 10.1111/j.1468-1293.2007.00533.x 18257769
37. Services DoHaH, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 2009 1 161
38. A simple and precise method for the routine determination of platelet-activating factor in blood and urine. Demopoulos CA, Andrikopoulos NK, Antonopoulou S, Lipids 1994 29 305 309 10.1007/BF02536336 8177023
39. A rapid method of total lipid extraction and purification. Bligh EG, Dyer WJ, Can J Biochem Physiol 1959 37 911 917 10.1139/o59-099 13671378
40. Platelet activating factor levels and metabolism in tangier disease: a case study. Kolovou V, Papakonstantinou VD, Stamatakis G, Verouti SN, Xanthopoulou MN, Kolovou G, Demopoulos CA, Lipids Health Dis 2012 11 89 10.1186/1476-511X-11-89 22769014
41. The role of HIV in serious diseases other than AIDS. Phillips AN, Neaton J, Lundgren JD, AIDS 2008 22 2409 2418 10.1097/QAD.0b013e3283174636 19005264
42. PAF and its metabolic enzymes in healthy volunteers: interrelations and correlations with basic characteristics. Detopoulou P, Nomikos T, Fragopoulou E, Stamatakis G, Panagiotakos DB, Antonopoulou S, Prostaglandins Other Lipid Mediat 2012 97 43 49 10.1016/j.prostaglandins.2011.10.003 22079887
43. Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target. Packard CJ, Curr Opin Cardiol 2009 24 358 363 10.1097/HCO.0b013e32832bcb22 19417639
44. Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Nowlan ML, Drewe E, Bulsara H, Esposito N, Robins RA, Tighe PJ, Powell RJ, Todd I, Rheumatology 2006 45 31 37 10.1093/rheumatology/kei090 16287931
45. Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1 alpha. Bussolino F, Camussi G, Baglioni C, J Biol Chem 1988 263 11856 11861 3261295
46. Tumor necrosis factor release by human monocytes stimulated with platelet-activating factor. Ruis NM, Rose JK, Valone FH, Lipids 1991 26 1060 1064 10.1007/BF02536502 1668105